MBX Biosciences (Ticker: MBX) is a clinical-stage biopharmaceutical company developing precision peptide therapies for the treatment of endocrine and metabolic diseases. Its lead drug candidate, MBX 2109, is a potential long-acting hormone replacement therapy for chronic hypoparathyroidism. MBX Biosciences, incorporated in Delaware, will list on NASDAQ on September 13, 2024.

The firm is offering 8.5 million shares at a price range of $14.00 to $16.00, aiming to raise $127.5 million. The expected market capitalization at the offer is $452.31 million. The offering is managed by JPMorgan, Jefferies, Stifel, and Guggenheim Securities.